Alto Neuroscience (ANRO) risk factors, FY2024 10-K

Other

1. 01Summary of Selected Risk Factors Associated with Our Business

Risks Related to Our Limited Operating History, Financial Position, and Need for Capital

1. 02We are a clinical-stage biopharmaceutical company with a limited operating history and no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of product candidates and the prospects for our future viability
2. 03We have incurred substantial losses since our inception. We anticipate incurring substantial and increasing losses for the foreseeable future and may never achieve or maintain profitability
3. 04We will require substantial additional financing to achieve our goals, and failure to obtain additional capital when needed, or on acceptable terms to us, could cause us to delay, limit, reduce, or terminate our product development or future commercialization efforts
4. 05The obligations from our license and asset acquisition agreements may cause dilution to our stockholders, may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations

Risks Related to Product Candidate Development and Commercialization

1. 06Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support the approval of our current or any future product candidates
2. 07Such collaborations may be subject to additional delays because of the management of the trials, contract negotiations, the need to obtain agreement from multiple parties, and may increase our future costs and expenses
3. 08We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
4. 09We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines
5. 10If we are unable to develop and obtain regulatory approval or clearance for the companion diagnostic tools needed to leverage our Platform, our business, financial condition, results of operations, and prospects could be materially and adversely affected
6. 11We have never commercialized a product candidate and may experience delays or unexpected difficulties in obtaining, or fail to obtain, regulatory approval for our product candidates
7. 12Additional time may be required to obtain marketing authorizations for any of our product candidates that we develop as drug/device combination products
8. 13Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us or any future collaboration partners from obtaining approvals for the commercialization of our product candidates
9. 14Interim, “topline,” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
10. 15If we fail to develop and commercialize our current product candidates for additional indications or fail to discover, develop, and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired
11. 16We may expend our resources to pursue a particular product candidate or indication and forgo the opportunity to capitalize on product candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success
12. 17Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
13. 18We may conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA may not accept data from such trials, in which case our development plans may be delayed, which could materially harm our business
14. 19Even if our product candidates receive regulatory approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable
15. 20that coverage and reimbursement in the United States, the EU, or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future

Risks Related to Our Business and Operations

1. 21We were founded with a mission to redefine neuropsychiatric drug development, a field that has seen very limited success. The ability to successfully develop drugs in this field is extremely difficult and is subject to a number of unique challenges
2. 22Our business depends on the success of our product candidates. If we are ultimately unable to successfully commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed
3. 23Lender or Wellcome pursuant to the Amended Loan Agreement or the Convertible Grant Agreement, respectively, or exercise of any warrants held by the Lender now or in the future would cause dilution to our stockholders
4. 24We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business
5. 25We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer
6. 26Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
7. 27Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties
8. 28Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could adversely affect our business, financial condition, results of operations, and prospects
9. 29have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring
10. 30Many of our operations are concentrated in California, and we or the third parties upon whom we depend may be adversely affected by a wildfire and earthquake or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
11. 31Our projections regarding the market opportunities for our product candidates may not be accurate, and the actual market for our products may be smaller than we estimate
12. 32Our business could be adversely affected by the effects of health pandemics or epidemics, which could cause significant disruptions in our operations and those of our current or future CMOs, CROs, and other third parties upon whom we rely

Risks Related to Collaborations, Intellectual Property, and Related Agreements

1. 33surpassing our achievements, thus eroding our competitive position in our market. We also rely on protection afforded by in-licensed intellectual property rights and proprietary technology of third parties
2. 34Issued patents covering our product candidates, or the method of use of our product candidates or associated companion diagnostics could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
3. 35We may not be successful in obtaining or maintaining necessary rights to third party patents for our product candidates through acquisitions and in-licenses
4. 36intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and our business, financial condition, results of operations, and prospects could suffer
5. 37commercializing product candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements
6. 38We may form or seek collaborations or strategic alliances, enter into additional licensing arrangements or other business transactions in the future, and we may not realize the benefits of such transactions
7. 39We may not be able to protect our intellectual property rights throughout the world
8. 40Intellectual property rights do not necessarily address all potential threats to our competitive advantage
9. 41We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our product candidates
10. 42We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful
11. 43Our product candidates licensed from various third parties may be subject to retained rights
12. 44Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
13. 45We may become subject to claims challenging the inventorship or ownership of our or our licensors’ patents and other intellectual property
14. 46Patent terms may be inadequate to protect our competitive position on products or product candidates for a sufficient amount of time
15. 47If we do not obtain patent term extension for our product candidate, our business may be materially harmed
16. 48Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated as a result of noncompliance with these requirements
17. 49If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
18. 50If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
19. 51rights of third parties, and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark
20. 52We may be subject to claims asserting that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property

Risks Related to Our Reliance on Third Parties

1. 53If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture product candidates may increase and commercialization may be delayed
2. 54increases in our studies for ALTO-101 and ALTO-203 or have other adverse effects on the development of our product candidates and our business operations
3. 55The operations of our suppliers that are located outside of the United States are subject to additional risks that are beyond our control and that could harm our business, financial condition, results of operations, and prospects
4. 56We may have conflicts with our current or future licensors or collaborators that could delay or prevent the development or commercialization of our product candidates
5. 57We have historically relied on an affiliated third party to provide certain business services and the replacement of such services could adversely affect our business operations
6. 58Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed

Risks Related to Government Regulation

1. 59The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical products
2. 60Drug marketing and reimbursement regulations in the EU may materially affect our ability to market and receive coverage for our products in the EU member states
3. 61observations. Accordingly, we and others with which we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control
4. 62The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
5. 63The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
6. 64Ongoing healthcare legislative and regulatory reform measures may adversely affect our business, results of operations, and financial condition
7. 65Additional laws and regulations governing international operations could adversely affect our business, results of operations and financial condition
8. 66or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs

Risks Related to Ownership of Our Common Stock and Our Status as a Public Company

1. 67An active and liquid trading market for our common stock may not continue to develop or be sustained
2. 68Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance we may publicly provide, each of which may cause our stock price to fluctuate or decline
3. 69Our stock price may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of shares of our common stock
4. 70We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
5. 71Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
6. 72We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
7. 73our operating results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new or revised accounting standards
8. 74Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders
9. 75Sales of a substantial number of our common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock
10. 76We have broad discretion in the use of our cash and cash equivalents and may not use them effectively, which could affect our results of operations and cause our stock price to decline
11. 77Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management, and limit the market price of our common stock
12. 78Our ability to use our net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited
13. 79Recent and future changes to tax laws could materially adversely affect our company
14. 80Unstable economic and market conditions may have serious adverse consequences on our business, financial condition, and stock price
15. 81If securities or industry analysts do not publish research or reports about our business, or if they publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
16. 82We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices
17. 83Failure to establish and maintain effective internal control over financial reporting could adversely affect our business and if investors lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be negatively affected
18. 84Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
19. 85We may be subject to securities litigation, which is expensive and could divert management attention